MOESM9 of Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy
2019-10-10T08:55:24Z (GMT) by
Additional file 9: Fifure S4. Landscape of potentially clinically actionable variants in plasma of LUAD. (A)Number of individuals for targeting therapy during chemotherapy and mutated frequency of genes. Pre (goldenrod1): patients have potential drug targets only in pre chemotherapy; Pre & Post (grey): patients have potential drug targets in pre and post chemotherapy; Post (indianred): patients have potential drug targets only in post chemotherapy). Each bar represented a category. (B) Number of individuals for targeting therapy, each bar represented a gene. (C) Variants in genes (rows) that may predict sensitivity to ERK-Signalling, PI3K/MTOR inhibitor. Vertical columns correspond to plasma samples.